BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol 2010;3:55-66. [PMID: 21180590 DOI: 10.1177/1756283X09346669] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Li G, Liu Y, Zhang Y, Xu Y, Zhang J, Wei X, Zhang Z, Zhang C, Feng J, Li Q, Wang G. A Novel Ferroptosis-Related Long Non-Coding RNA Prognostic Signature Correlates With Genomic Heterogeneity, Immunosuppressive Phenotype, and Drug Sensitivity in Hepatocellular Carcinoma. Front Immunol 2022;13:929089. [DOI: 10.3389/fimmu.2022.929089] [Reference Citation Analysis]
2 Qian X, Wang Y, Hu W, Xu X, Gao L, Meng Y, Yan J. MiR-369-5p inhibits the proliferation and migration of hepatocellular carcinoma cells by down-regulating HOXA13 expression. Tissue and Cell 2022;74:101721. [DOI: 10.1016/j.tice.2021.101721] [Reference Citation Analysis]
3 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
4 Xu L, Jian X, Liu Z, Zhao J, Zhang S, Lin Y, Xie L. Construction and Validation of an Immune Cell Signature Score to Evaluate Prognosis and Therapeutic Efficacy in Hepatocellular Carcinoma. Front Genet 2021;12:741226. [PMID: 34646307 DOI: 10.3389/fgene.2021.741226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Kaur H, Lathwal A, Raghava GP. Integrative multi-omics approach for stratification of tumor recurrence risk groups of Hepatocellular Carcinoma patients.. [DOI: 10.1101/2021.03.03.433841] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cheng X, Zhang Y, Song F, Song F, Gao C, Liang X, Wang F, Chen Z. URM1 Promoted Tumor Growth and Suppressed Apoptosis via the JNK Signaling Pathway in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:8011-25. [PMID: 32848422 DOI: 10.2147/OTT.S258843] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jeng KS, Lu SJ, Wang CH, Chang CF. Liver Fibrosis and Inflammation under the Control of ERK2. Int J Mol Sci 2020;21:E3796. [PMID: 32471201 DOI: 10.3390/ijms21113796] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
8 Nabrinsky E, James E. Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma. Cureus 2020;12:e8163. [PMID: 32550079 DOI: 10.7759/cureus.8163] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Dadfar SMM, Sekula-Neuner S, Trouillet V, Liu HY, Kumar R, Powell AK, Hirtz M. Evaluation of click chemistry microarrays for immunosensing of alpha-fetoprotein (AFP). Beilstein J Nanotechnol 2019;10:2505-15. [PMID: 31921529 DOI: 10.3762/bjnano.10.241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
10 Zhang Y, Wang S, Liu Z, Yang L, Liu J, Xiu M. Increased Six1 expression in macrophages promotes hepatocellular carcinoma growth and invasion by regulating MMP-9. J Cell Mol Med 2019;23:4523-33. [PMID: 31044528 DOI: 10.1111/jcmm.14342] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
11 Wang LK, Xie XN, Song XH, Su T, Chang XL, Xu M, Liang B, Huang DY. Upregulation of miR-200b Inhibits Hepatocellular Carcinoma Cell Proliferation and Migration by Targeting HMGB3 Protein. Technol Cancer Res Treat 2018;17:1533033818806475. [PMID: 30343649 DOI: 10.1177/1533033818806475] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
12 Zhang X, Wang L, Zhang H, Tu F, Qiang Y, Nie C. Decreased expression of ZO-1 is associated with tumor metastases in liver cancer. Oncol Lett. 2019;17:1859-1864. [PMID: 30675248 DOI: 10.3892/ol.2018.9765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
13 Ke R, Lv L, Li J, Zhang X, Yang F, Zhang K, Jiang Y. Prognostic value of heterogeneous ribonucleoprotein A1 expression and inflammatory indicators for patients with surgically resected hepatocellular carcinoma: Perspectives from a high occurrence area of hepatocellular carcinoma in China. Oncol Lett 2018;16:3746-56. [PMID: 30127985 DOI: 10.3892/ol.2018.9079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
14 Hou G, Liu G, Yang Y, Li Y, Yuan S, Zhao L, Wu M, Liu L, Zhou W. Neuraminidase 1 (NEU1) promotes proliferation and migration as a diagnostic and prognostic biomarker of hepatocellular carcinoma. Oncotarget 2016;7:64957-66. [PMID: 27602751 DOI: 10.18632/oncotarget.11778] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
15 Maioli M, Basoli V, Carta P, Fabbri D, Dettori MA, Cruciani S, Serra PA, Delogu G. Synthesis of magnolol and honokiol derivatives and their effect against hepatocarcinoma cells. PLoS One. 2018;13:e0192178. [PMID: 29415009 DOI: 10.1371/journal.pone.0192178] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
16 Ma D, Shen B, Seewoo V, Tong H, Yang W, Cheng X, Jin Z, Peng C, Qiu W. GADD45β induction by S-adenosylmethionine inhibits hepatocellular carcinoma cell proliferation during acute ischemia-hypoxia. Oncotarget 2016;7:37215-25. [PMID: 27177086 DOI: 10.18632/oncotarget.9295] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
17 Kuruvilla SP, Tiruchinapally G, Crouch AC, ElSayed MEH, Greve JM. Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model. PLoS One 2017;12:e0181944. [PMID: 28829785 DOI: 10.1371/journal.pone.0181944] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
18 Li J, Wang J, Zhou W, Zhang S, Le Y, He R. Downregulation of BRAF-activated non-coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells. Oncol Lett 2017;14:4751-7. [PMID: 29085476 DOI: 10.3892/ol.2017.6770] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
19 Chuang TY, Wu HL, Min J, Diamond M, Azziz R, Chen YH. Berberine regulates the protein expression of multiple tumorigenesis-related genes in hepatocellular carcinoma cell lines. Cancer Cell Int 2017;17:59. [PMID: 28572744 DOI: 10.1186/s12935-017-0429-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
20 Chao MW, Chen TH, Huang HL, Chang YW, HuangFu WC, Lee YC, Teng CM, Pan SL. Lanatoside C, a cardiac glycoside, acts through protein kinase Cδ to cause apoptosis of human hepatocellular carcinoma cells. Sci Rep 2017;7:46134. [PMID: 28387249 DOI: 10.1038/srep46134] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
21 Cao Y, Ke R, Wang S, Zhu X, Chen J, Huang C, Jiang Y, Lv L. DNA topoisomerase IIα and Ki67 are prognostic factors in patients with hepatocellular carcinoma. Oncol Lett 2017;13:4109-16. [PMID: 28599412 DOI: 10.3892/ol.2017.5999] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
22 Wang Y, Luo Y, Li C, Zhang X, Pi C, Yu L, Wang S, Zhong Z. Optimized formulation of multivesicular liposomes loaded with oleanolic acid enhanced anticancer effect in vitro. Drug Des Devel Ther 2017;11:955-68. [PMID: 28392677 DOI: 10.2147/DDDT.S128795] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
23 Li A, Yan Q, Zhao X, Zhong J, Yang H, Feng Z, Du Y, Wang Y, Wang Z, Wang H, Zhou Y, Liu S, Nie Y. Decreased expression of PBLD correlates with poor prognosis and functions as a tumor suppressor in human hepatocellular carcinoma. Oncotarget 2016;7:524-37. [PMID: 26594798 DOI: 10.18632/oncotarget.6358] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
24 Wang F, Qiang Y, Zhu L, Jiang Y, Wang Y, Shao X, Yin L, Chen J, Chen Z. MicroRNA-7 downregulates the oncogene VDAC1 to influence hepatocellular carcinoma proliferation and metastasis. Tumour Biol 2016;37:10235-46. [PMID: 26831666 DOI: 10.1007/s13277-016-4836-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
25 Li Y, Tu M, Cheng C, Tian J, Zhang F, Deng Z, Li X, Li Z, Liu Y, Lei G. Wogonoside induces apoptosis in Bel-7402, a hepatocellular carcinoma cell line, by regulating Bax/Bcl-2. Oncol Lett 2015;10:1831-5. [PMID: 26622760 DOI: 10.3892/ol.2015.3408] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
26 Ku CY, Wang YR, Lin HY, Lu SC, Lin JY. Corosolic Acid Inhibits Hepatocellular Carcinoma Cell Migration by Targeting the VEGFR2/Src/FAK Pathway. PLoS One 2015;10:e0126725. [PMID: 25978354 DOI: 10.1371/journal.pone.0126725] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
27 Yang L, Hu B, Zhang Y, Qiang S, Cai J, Huang W, Gong C, Zhang T, Zhang S, Xu P, Wu X, Liu J. Suppression of the nuclear transporter-KPNβ1 expression inhibits tumor proliferation in hepatocellular carcinoma. Med Oncol 2015;32:128. [PMID: 25794490 DOI: 10.1007/s12032-015-0559-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
28 Huang W, Gao F, Li K, Wang W, Lai YR, Tang SH, Yang DH. Decaprenyl diphosphate synthase subunit 2 as a prognosis factor in hepatocellular carcinoma. World J Gastroenterol 2015; 21(10): 3055-3065 [PMID: 25780306 DOI: 10.3748/wjg.v21.i10.3055] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Li J, Fang L, Yu W, Wang Y. MicroRNA-125b suppresses the migration and invasion of hepatocellular carcinoma cells by targeting transcriptional coactivator with PDZ-binding motif. Oncol Lett 2015;9:1971-5. [PMID: 25789078 DOI: 10.3892/ol.2015.2973] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
30 Nair SV, Ziaullah, Rupasinghe HP. Fatty acid esters of phloridzin induce apoptosis of human liver cancer cells through altered gene expression. PLoS One 2014;9:e107149. [PMID: 25229655 DOI: 10.1371/journal.pone.0107149] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
31 Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, Scholz A. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia. 2013;15:1161-1171. [PMID: 24204195 DOI: 10.1593/neo.13812] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
32 Hu B, Xiong Y, Ni R, Wei L, Jiang D, Wang G, Wu D, Xu T, Zhao F, Zhu M. The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma. Mol Cell Biochem. 2014;396:175-185. [PMID: 25081333 DOI: 10.1007/s11010-014-2153-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
33 Tang K, Luo C, Li Y, Lu C, Zhou W, Huang H, Chen X. The study of a novel sorafenib derivative HLC-080 as an antitumor agent. PLoS One 2014;9:e101889. [PMID: 25004130 DOI: 10.1371/journal.pone.0101889] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
34 Hu S, Wu X, Zhou B, Xu Z, Qin J, Lu H, Lv L, Gao Y, Deng L, Yin J. IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2014;140:883-893. [PMID: 24647926 DOI: 10.1007/s00432-014-1639-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
35 Yao M, Wang L, Dong Z, Qian Q, Shi Y, Yu D, Wang S, Zheng W, Yao D. Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy. Tumour Biol. 2014;35:5857-5868. [PMID: 24633918 DOI: 10.1007/s13277-014-1776-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
36 Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, Li Q, Zhang Y, Ding Y, Chen B, Chen L. MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One 2014;9:e88393. [PMID: 24551096 DOI: 10.1371/journal.pone.0088393] [Cited by in Crossref: 59] [Cited by in F6Publishing: 69] [Article Influence: 6.6] [Reference Citation Analysis]
37 Hussin F, Eshkoor SA, Rahmat A, Othman F, Akim A. The centella asiatica juice effects on DNA damage, apoptosis and gene expression in hepatocellular carcinoma (HCC). BMC Complement Altern Med 2014;14:32. [PMID: 24444147 DOI: 10.1186/1472-6882-14-32] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
38 Thakolwiboon S, Zhu J, Liang Q, Welling TH, Zhang M, Lubman DM. Heterogeneity of The CD90+ Population in Different Stages of Hepatocarcinogenesis. J Proteomics Bioinform 2014;7:296-302. [PMID: 25580065 DOI: 10.4172/jpb.1000332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
39 Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574-583. [PMID: 24388934 DOI: 10.1016/j.ajpath.2013.10.028] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
40 Loarca L, Sassi-Gaha S, Artlett CM. Two α-dicarbonyls downregulate migration, invasion, and adhesion of liver cancer cells in a p53-dependent manner. Dig Liver Dis 2013;45:938-46. [PMID: 24071451 DOI: 10.1016/j.dld.2013.05.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
41 Peng H, Lin I, Lee C, Wang L, Tzeng C, Chang J, Yang S. Synthesis and antitumor activity evaluation of anilinoquinoline derivatives by the effect on the expression of polo-like kinase. Med Chem Res 2014;23:1437-46. [DOI: 10.1007/s00044-013-0749-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Siegel AB, Narayan R, Rodriguez R, Goyal A, Jacobson JS, Kelly K, Ladas E, Lunghofer PJ, Hansen RJ, Gustafson DL. A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther. 2014;13:46-53. [PMID: 23757319 DOI: 10.1177/1534735413490798] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
43 Joo I, Choi BI. New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer 2012;1:94-109. [PMID: 24159577 DOI: 10.1159/000342404] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]